Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.36 |
| ▸ | GABRP | O00591 | 1/20 | 0.35 |
| ▸ | GABRD | O14764 | 1/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.35 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.35 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.35 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.35 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.35 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.35 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.35 |
| ▸ | GABRE | P78334 | 1/20 | 0.35 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.35 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.35 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.35 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5750787 | 0.97 | KDM4E (0.35) | KDM4EKMT2AOPRM1GABRPGABRD | |
| SCHEMBL1855601 | 0.84 | — | — | |
| Hydrochloric Acid SCHEMBL11546148 | 0.82 | HTR2A (0.34) | — | |
| SCHEMBL28736616 | 0.82 | KDM4E (0.35) | KDM4EKMT2AOPRM1 | |
| Toluene SCHEMBL27914297 | 0.80 | OPRM1 (0.46) | KMT2AOPRM1GABRDGABRA1TSHR | |
| SCHEMBL153693 | 0.78 | — | — | |
| SCHEMBL61405 | 0.76 | KDM4E (0.50) | KDM4EKMT2AOPRM1DRD2 | |
| SCHEMBL7286601 | 0.76 | KDM4E (0.40) | KDM4EKMT2AOPRM1GABRDGABRA1 | |
| SCHEMBL6757053 | 0.76 | — | — | |
| SCHEMBL825722 | 0.74 | KDM4E (0.38) | KDM4EKMT2AOPRM1GABRPGABRD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 146 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114349922-A | Flexible dual-curing resin composition and preparation method of forming body thereof | 浙江华峰新材料有限公司 | 2022-04-15 | — | — | CN | claimed |
| CN-109863146-A | Aryl-linking compound as immunomodulator | 百时美施贵宝公司 | 2019-06-07 | — | — | CN | claimed |
| US-20250026749-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION (US) | 2025-01-23 | — | — | US | disclosed |
| US-12180226-B2 | Spirotricycle RIPK1 inhibitors and methods of uses thereof | MERCK SHARP & DOHME LLC (US) | 2024-12-31 | — | — | US | disclosed |
| EP-4423096-A1 | SPIROTRICYCLE RIPK1 INHIBITORS AND METHODS OF USES THEREOF | Merck Sharp & Dohme LLC (US) | 2024-09-04 | — | — | EP | disclosed |
| US-20240277706-A1 | METHODS AND COMPOSTITIONS FOR TARGETING PD-L1 | ALIGOS THERAPEUTICS, INC. | 2024-08-22 | — | — | US | disclosed |
| US-12060349-B2 | Glucosylceramide synthase inhibitors | GENZYME CORPORATION (US) | 2024-08-13 | — | — | US | disclosed |
| CN-118488957-A | Spirotricyclic RIPK1 inhibitors and methods of use thereof | 默沙东有限责任公司 | 2024-08-13 | — | — | CN | disclosed |
| US-20230348427-A1 | COMPOUND FOR ANDROGEN RECEPTOR DEGRADATION, AND PHARMACEUTICAL USE THEREOF | UBIX THERAPEUTICS, INC. (KR) | 2023-11-02 | — | — | US | disclosed |
| EP-3998260-B1 | SGC STIMULATORS | CYCLERION THERAPEUTICS INC (US) | 2023-11-01 | — | — | EP | disclosed |
| EP-4240736-A1 | PPAR GAMMA MODULATORS AND METHODS OF USE | Eisai R&D Management Co., Ltd. (JP) | 2023-09-13 | — | — | EP | disclosed |
| US-6576627-B1 | Such as 7-amino-2-((2-methyl-1-(3-phenylpropanoylamino)-propyl)hydroxyphosphinoyl) -methylheptanoic acid; thrombotic disease | MEIJI SEIKA KAISHA LTD. (JP) | 2003-06-10 | — | — | US | disclosed |
| EP-1152004-B1 | Phosphonic acid derivatives having carboxypeptidase B inhibitory action | MEIJI SEIKA KAISHA (JP) | 2003-05-07 | — | — | EP | disclosed |
| WO-2003010138-A2 | PIPERIDINE DERIVATIVES AS ANTIBACTERIAL AGENTS | SMITHKLINE BEECHAM PLC (GB) | 2003-02-06 | — | — | WO | disclosed |
| CN-1373766-A | Phosphonic acid derivatives having carboxypeptidase B inhibitory activity | MEIJI SEIKA KAISHA (JP) | 2002-10-09 | — | — | CN | disclosed |
| EP-1174434-A1 | Phosphonic acid derivative having inhibitory activity against carboxypeptidase B | MEIJI SEIKA KAISHA LTD. (JP) | 2002-01-23 | — | — | EP | disclosed |
| EP-1152004-A1 | PHOSPHONIC ACID DERIVATIVES HAVING CARBOXYPEPTIDASE B INHIBITORY ACTIVITY | MEIJI SEIKA KAISHA LTD. (JP) | 2001-11-07 | — | — | EP | disclosed |
| CN-1052231-C | Adhesion receptor antagonists | MERCK PATENT GMBH (DE) | 2000-05-10 | — | — | CN | disclosed |
| CN-1097421-A | Adhesion receptor antagonists | MERCK PATENT GMBH (DE) | 1995-01-18 | — | — | CN | disclosed |
| US-4247694-A | PHOTOSTABILIZERS FOR POLYMERS | CIBA-GEIGY CORPORATION (US) | 1981-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240277706-A1 | METHODS AND COMPOSTITIONS FOR TARGETING PD-L1 | CD274, PDCD1, PDCD1LG2 | KDM4E 2919/4885KMT2A 2875/4885OPRM1 2759/4885 |
| US-20230348427-A1 | COMPOUND FOR ANDROGEN RECEPTOR DEGRADATION, AND PHARMACEUTICAL USE THEREOF | AR, NR5A1, SHBG | KDM4E 2263/4885KMT2A 2131/4885OPRM1 984/4885 |
| US-12060349-B2 | Glucosylceramide synthase inhibitors | GBA1, GBA2, GALC | KDM4E 4213/4885KMT2A 2942/4885OPRM1 4766/4885 |
| US-20250026749-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, GBA2, GAA | KDM4E 4241/4885KMT2A 2721/4885OPRM1 4772/4885 |
| US-12180226-B2 | Spirotricycle RIPK1 inhibitors and methods of uses thereof | RIPK1, RIPK3, RIPK4 | KDM4E 3571/4885KMT2A 3659/4885OPRM1 4667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.